In terms of treatment, DMTs are mainly used for MS remission, including IFN-β, Glatiramer acetate, Teriflunomide, Dimethyl fumarate, Fingolimod, Ocrelizumab, Alemtuzumab, Natalizumab, and Mitoxantrone, etc. Among them, IFN-β and Fingolimod are widely used in early clinical practice with significant efficacy. Here, IFNB1 is linked to myeloid sarcoma.